Dexamethasone should be used for COVID-19 treatment only under close supervision, Director-General of the World Health Organization Tedros Adhanom Ghebreyesus said Wednesday.
A widely available steroid treatment, dexamethasone, can significantly improve survival rates of severe coronavirus patients, a statement on trial results published Tuesday said.
"These drugs should only be used under close clinical supervision," Tedros told a virtual briefing.
The WHO chief stressed that dexamethasone was shown to not have a beneficial effect for those with milder disease, only the severe cases.
According to Tedros, WHO is coordinating an analysis of data from several clinical trials to better understand how efficient the drug is.
The drug should not be used as a preventive measure either, Mike Ryan, the executive director for WHO Health Emergencies Programme, said.
"This is not for mild cases. This is not for prophylaxis. This is a very, very powerful anti-inflammatory drug. It can rescue patients, who are in very serious condition," Ryan told a virtual briefing.
The medication does not treat the virus itself, Ryan said, adding that steroid might even "facilitate the division and replication of viruses in human bodies." The WHO official then underscored, once again, the importance of clinical supervision for the use of the drug.
Ryan said countries should take measured approach to use of dexamethasone, adding that it was 'not the time to rush to change clinical practice'.